[{"orgOrder":0,"company":"Insignis Therapeutics","sponsor":"HLK Pharmacin","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"IN-001","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"Insignis Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Insignis Therapeutics \/ HLK Pharmacin","highestDevelopmentStatusID":"5","companyTruncated":"Insignis Therapeutics \/ HLK Pharmacin"},{"orgOrder":0,"company":"Insignis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Epinephrine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Insignis Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Insignis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Insignis Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Insignis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Epinephrine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Insignis Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Insignis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Insignis Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Insignis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Epinephrine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Insignis Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Insignis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Insignis Therapeutics \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Insignis Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : IN-001 is a sublingual spray that utilizes an FDA-approved epinephrine prodrug, allowing for rapid administration without needles. It is being evaluated for the treatment of anaphylaxis.

                          Brand Name : IN-001-Prodrug

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          November 05, 2024

                          Lead Product(s) : Epinephrine

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : IN-001 (epinephrine) is an adrenergic receptor agonist, small molecule drug candidate which is being evaluated for the treatment of anaphylaxis.

                          Brand Name : IN-001

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 07, 2024

                          Lead Product(s) : Epinephrine

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : IN-001 is a sublingual spray that utilizes an FDA-approved epinephrine prodrug, allowing for rapid administration without needles. It is being evaluated for the treatment of anaphylaxis.

                          Brand Name : IN-001

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 13, 2024

                          Lead Product(s) : Epinephrine

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The Phase 1 single dose study in healthy volunteers will compare IN-001 orally dissolving tablet (epinephrine prodrug) vs the current standard of care, EPIPEN (epinephrine injection).

                          Brand Name : IN-001

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 29, 2020

                          Lead Product(s) : IN-001

                          Therapeutic Area : Immunology

                          Highest Development Status : IND Enabling

                          Sponsor : HLK Pharmacin

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank